Knockdown of lncRNA NUTM2A‑AS1 inhibits lung adenocarcinoma cell viability by regulating the miR‑590‑5p/METTL3 axis

Wang,Jie; Zha,Jingyun; Wang,Xiaolin

doi:10.3892/ol.2021.13059

Knockdown of lncRNA NUTM2A‑AS1 inhibits lung adenocarcinoma cell viability by regulating the miR‑590‑5p/METTL3 axis

Authors:
- Jie Wang
- Jingyun Zha
- Xiaolin Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China, Department of Respiratory Medicine, Hefei First People's Hospital, Hefei, Anhui 230001, P.R. China
Published online on: September 20, 2021 https://doi.org/10.3892/ol.2021.13059
Article Number: 798
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma (LUAD) is the leading cause of cancer‑related mortality worldwide. Long non‑coding RNA (lncRNA) NUT family member 2A antisense RNA 1 (NUTM2A‑AS1) is dysregulated in LUAD; however, its role in this disease remains unclear. The present study aimed to identify the underlying molecular mechanism of the effect of lncRNA NUTM2A‑AS1 in LUAD by exploring whether lncRNA NUTM2A‑AS1 could affect LUAD cell proliferation and apoptosis through the microRNA (miR)‑590‑5p/methyltransferase 3, N6‑adenosine‑methyltransferase complex catalytic subunit (METTL3) axis. miR‑590‑5p was predicted and verified as the direct target of NUTM2A‑AS1 using bioinformatics analysis and a dual luciferase reporter assay. The expression levels of NUTM2A‑AS1 and miR‑590‑5p in lung cancer cells, and the effects of NUTM2A‑AS1 on cell viability and apoptosis were determined using MTT assays and flow cytometry, respectively. Reverse transcription‑quantitative PCR analysis revealed that the expression levels of NUTM2A‑AS1 were significantly upregulated, while those of miR‑590‑5p were significantly downregulated, in lung cancer cells compared with the control epithelial cells. NUTM2A‑AS1 knockdown inhibited NCI‑H23 cell viability and induced apoptosis by upregulating miR‑590‑5p expression. Moreover, the function and regulatory mechanism of miR‑590‑5p in LUAD were also investigated. It was determined that miR‑590‑5p could interact with METTL3, and further analysis of the expression levels of METTL3 in lung cancer cells demonstrated that METTL3 was significantly upregulated in NCI‑H23 and A549 cells compared with the control cells. In addition, miR‑590‑5p inhibited NCI‑H23 cell viability and induced apoptosis by downregulating METTL3 expression. In conclusion, the findings of the present study suggested that NUTM2A‑AS1 knockdown may inhibit LUAD progression by regulating the miR‑590‑5p/METTL3 axis. These results may provide insight into the mechanisms underlying the tumorigenesis of LUAD and offer a new treatment strategy for the disease.

View Figures

View References

1	Chang JT, Lee YM and Huang RS: The impact of the cancer genome atlas on lung cancer. Transl Res. 166:568–585. 2015. View Article : Google Scholar : PubMed/NCBI
2	Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, et al: An expression signature as an aid to the histologic classification of non-small cell lung cancer. Clin Cancer Res. 22:4880–4889. 2016. View Article : Google Scholar : PubMed/NCBI
3	Sardenberg RA, Pinto C, Bueno CA and Younes RN: Non-small cell lung cancer stage IV long-term survival with isolated spleen metastasis. Ann Thorac Surg. 95:1432–1434. 2013. View Article : Google Scholar : PubMed/NCBI
4	Travis WD: Pathology of lung cancer. Clin Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
5	Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA and Johnson BE: Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 11:556–565. 2016. View Article : Google Scholar : PubMed/NCBI
7	Peng FD, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z, Liang H, Zhao W, Qi L, Guo Z and Gu Y: Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 16:982017. View Article : Google Scholar : PubMed/NCBI
8	Fatica A and Bozzoni I: Long non-coding RNAs: New players in cell differentiation and development. Nat Rev Genet. 15:7–21. 2014. View Article : Google Scholar : PubMed/NCBI
9	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
10	Li J, Meng H, Bai Y and Wang K: Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 23:205–217. 2016. View Article : Google Scholar : PubMed/NCBI
11	Acha-Sagredo A, Uko B, Pantazi P, Bediaga NG, Moschandrea C, Rainbow L, Marcus MW, Davies MPA, Field JK and Liloglou T: Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. Br J Cancer. 122:1050–1058. 2020. View Article : Google Scholar : PubMed/NCBI
12	Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T and Yousefi M: MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother. 74:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhao K, Cheng J, Chen BJ, Liu Q, Xu D and Zhang Y: Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer. J Thorac Dis. 9:3735–3746. 2017. View Article : Google Scholar : PubMed/NCBI
14	Moretti F, D'Antona P, Finardi E, Barbetta M, Dominioni L, Poli A, Gini E, Noonan DM, Imperatori A, Rotolo N, et al: Systematic review and critique of circulating miRNAs as biomarkers of stage I–II non-small cell lung cancer. Oncotarget. 8:94980–94996. 2017. View Article : Google Scholar : PubMed/NCBI
15	Khandelwal A, Seam RK, Gupta M, Rana MK, Prakash H, Vasquez KM and Jain A: Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer. Cancer Sci. 111:826–839. 2020. View Article : Google Scholar : PubMed/NCBI
16	Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M, Tsukahara T and Suzuki T: The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem Biophys Res Commun. 524:150–155. 2020. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Feng J, Xue Y, Guan ZY, Zhang DL, Liu Z, Gong Z, Wang Q, Huang JB, Tang C, et al: Structural basis of N (6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 534:575–578. 2016. View Article : Google Scholar : PubMed/NCBI
18	Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, Zhang X, Cao Y, Ma D, Zhu X, et al: m⁶A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 19:722020. View Article : Google Scholar : PubMed/NCBI
19	Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, Zheng H and Li B: The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun. 512:479–485. 2019. View Article : Google Scholar : PubMed/NCBI
20	Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue Q, Wang D, Huang J, Gao S and Gao Y: MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun. 482:582–589. 2017. View Article : Google Scholar : PubMed/NCBI
21	Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, et al: m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 12:1352019. View Article : Google Scholar : PubMed/NCBI
22	He RZ, Jiang J and Luo DX: The functions of N6-methyladenosine modification in lncRNAs. Genes Dis. 7:598–605. 2020. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Schmitz SU, Grote P and Herrmann BG: Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 73:2491–2509. 2016. View Article : Google Scholar : PubMed/NCBI
25	Khandelwal A, Bacolla A, Vasquez K and Jain A: Long non-coding RNA: A new paradigm for lung cancer. Mol Carcinog. 54:1235–1251. 2015. View Article : Google Scholar : PubMed/NCBI
26	Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, Sato I, Takahashi S, Kondo T and Satoh K: Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochem Biophys Res Commun. 436:319–324. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wu Y, Liu HB, Shi XF, Yao YW, Yang W and Song Y: The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget. 6:9160–9172. 2015. View Article : Google Scholar : PubMed/NCBI
28	Li N, Gao WJ and Liu NS: LncRNA BCAR4 promotes proliferation, invasion and metastasis of non-small cell lung cancer cells by affecting epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci. 21:2075–2086. 2017.PubMed/NCBI
29	Schmidt LH, Spieker T, Koschmieder S, Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, et al: The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 6:1984–1992. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Yu ZY, Wang J, Shen Y, Qiu JL and Zhuang Z: LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a. Cancer Med. 9:9499–9510. 2020. View Article : Google Scholar : PubMed/NCBI
31	Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
32	Carthew RW and Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zheng GD, Xu ZY, Hu C, Lv H, Xie HX, Huang T, Zhang YQ, Chen GP, Fu YF and Cheng XD: Exosomal miR-590-5p in serum as a biomarker for the diagnosis and prognosis of gastric cancer. Front Mol Biosci. 8:6365662021. View Article : Google Scholar : PubMed/NCBI
34	Yan TY, Wang WH, Yang L, Chen KW, Chen R and Han Y: Rich club disturbances of the human connectome from subjective cognitive decline to Alzheimer's disease. Theranostics. 8:3237–3255. 2018. View Article : Google Scholar : PubMed/NCBI
35	Shen B, Yu S, Zhang Y, Yuan Y, Li XY, Zhong J and Feng J: miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets Ther. 9:6009–6019. 2016. View Article : Google Scholar : PubMed/NCBI
36	Jiang XF, Xiang G, Wang Y, Zhang L, Yang X, Cao L, Peng H, Xue P and Chen D: MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-β RII. Mol Cells. 33:545–551. 2012. View Article : Google Scholar : PubMed/NCBI
37	Cai W, Xu Y, Yin J, Zuo W and Su Z: miR-590-5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5. Mol Med Rep. 18:2328–2334. 2018.PubMed/NCBI
38	Mou K, Ding M, Han D, Zhou Y, Mu X, Liu W and Wang L: miR-590-5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression. Oncol Rep. 40:2056–2066. 2018.PubMed/NCBI
39	Jiang Z, Zhang J, Chen F and Sun Y: MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway. Thorac Cancer. 11:415–425. 2020. View Article : Google Scholar : PubMed/NCBI
40	Wang J, Wang Y, Sun D, Bu J, Ren F, Liu B, Zhang S, Xu Z, Pang S and Xu S: miR-455-5p promotes cell growth and invasion by targeting SOCO3 in non-small cell lung cancer. Oncotarget. 8:1149562017. View Article : Google Scholar : PubMed/NCBI
41	Pang HY, Zheng YR, Zhao Y, Xiu XQ and Wang JJ: miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 468:739–745. 2015. View Article : Google Scholar : PubMed/NCBI
42	Xu BB, Gu ZF, Ma M, Wang JY and Wang HN: MicroRNA-590-5p suppresses the proliferation and invasion of non-small cell lung cancer by regulating GAB1. Eur Rev Med Pharmacol Sci. 22:5954–5963. 2018.PubMed/NCBI
43	Wang TY, Kong S, Tao M and Ju SQ: The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 19:882020. View Article : Google Scholar : PubMed/NCBI
44	Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL, Lv JW, Huang XD, Liu RQ, Chen FP, He XJ, et al: Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. Cancer Res. 79:4612–4626. 2019. View Article : Google Scholar : PubMed/NCBI
45	Wei WW, Huo BS and Shi XL: miR-600 inhibits lung cancer via downregulating the expression of METTL3. Cancer Manag Res. 11:1177–1187. 2019. View Article : Google Scholar : PubMed/NCBI
46	Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M, Zhang J, Ren X, Wang Y, Yang X, et al: m⁶A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 9:11692018. View Article : Google Scholar : PubMed/NCBI
47	Chao YH, Shang J and JI WD: ALKBH5-m⁶A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. Biochem Biophys Res Commun. 521:499–506. 2020. View Article : Google Scholar : PubMed/NCBI
48	Lin S, Choe J, Du P, Triboulet R and Gregory R: The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
49	Wang P, Doxtader KA and Nam Y: Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 63:306–317. 2016. View Article : Google Scholar : PubMed/NCBI